Intensive Care Sedation

  • M. P. Shelly
Part of the Yearbook of Intensive Care and Emergency Medicine book series (YEARBOOK, volume 1992)


Attitudes to the sedation of critically patients has changed considerably in the past ten years. In 1981, Merriman [1] reported a survey of intensive care units (ICU). He found that 67% of the units preferred their patients to be deeply sedated and unaware of their surroundings. The patients were wakened only occasionally and 91% ICU surveyed used neuromuscular blocking agents frequently. In 1987, Bion and Ledingham [2], again surveyed ICU. In this study, 69% of responding units preferred patients to be asleep but easily rouseable, and only 16% used muscle relaxants frequently. Increasing knowledge of the risks associated with sedative agents and techniques has influenced the practice of sedation in intensive care.


Neuromuscular Blockade Sedation Score Neuromuscular Blocking Agent Sedative Agent Intensive Therapy Unit 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Merriman HM (1981) The techniques used to sedate ventilated patients. Intensive Care Med 7:217–224PubMedCrossRefGoogle Scholar
  2. 2.
    Bion JF, Ledingham IMcA (1987) Sedation in intensive care—a postal survey. Intensive Care Med 13:215–216PubMedGoogle Scholar
  3. 3.
    Bion JF (1988) Sedation and analgesia in the intensive care unit. Hospital Update 14:1272–1286Google Scholar
  4. 4.
    Keep P, James J, Inman M (1980) Windows in the intensive therapy unit. Anaesthesia 35:257–262PubMedCrossRefGoogle Scholar
  5. 5.
    Gamble JAS, Dundee JW, Gray RC (1976) Plasma diazepam concentrations following prolonged administration. Br J Anaesth 48:1087–1090PubMedCrossRefGoogle Scholar
  6. 6.
    Ochs HR, Greenblatt DJ, Eckhardt B, Harmatz JS, Shader RI (1983) Repeated diazepam dosing in cirrhotic patients: cumulation and sedation. Clin Pharm Ther 33:471–476CrossRefGoogle Scholar
  7. 7.
    Lebowitz PW, Cote ME, Daniels AL, Bonventre JV (1983) Comparative renal effects of midazolam and thiopental in humans. Anesthesiology 59:381–384PubMedCrossRefGoogle Scholar
  8. 8.
    Heizmann P, Eckert M, Ziegler WH (1983) Pharmacokinetics and bioavailability of midazolam in man. Br J Clin Pharm 16:43S-49SGoogle Scholar
  9. 9.
    Dundee JW, Collier PS, Carlisle RJT, Harper KW (1986) Prolonged midazolam elimination half-life. Br J Clin Pharm 21:425–429Google Scholar
  10. 10.
    Shelly MP, Mendel L, Park GR (1987) Failure of critically ill patients to metabolise midazolam. Anaesthesia 42:619–626PubMedCrossRefGoogle Scholar
  11. 11.
    Park GR, Manara AR, Dawling S (1989) Extrahepatic metabolism of midazolam. Br J Clin Pharm 27:633–634Google Scholar
  12. 12.
    Aitkenhead AR, Pepperman ML, Willatts SM, et al. (1989) Comparison of propofol and midazolam for sedation in critically ill patients. Lancet 2:704–709PubMedCrossRefGoogle Scholar
  13. 13.
    Amos RJ, Amess JAL, Hinds CJ, Mollin DL (1982) Incidence and pathogenesis of acute bone megaloblastic marrow change in patients receiving intensive care. Lancet 2:835–837PubMedCrossRefGoogle Scholar
  14. 14.
    Kong KL, Willatts SM, Prys-Roberts C (1989) Isoflurane compound compared with midazolam for sedation in the intensive care unit. Br Med J 298:1277–1279CrossRefGoogle Scholar
  15. 15.
    Truog RD, Rice SA (1989) Inorganic fluoride and prolonged isoflurane anesthesia in the intensive care unit. Anesth Analg 69:843–845PubMedCrossRefGoogle Scholar
  16. 16.
    Gray PA, Park GR (1989) Chlormethiazole sedation for critically ill patients in renal failure. Anaesthesia 44:913–915PubMedCrossRefGoogle Scholar
  17. 17.
    Shimomura K, Kamata O, Ueki S, et al. (1986) Analgesic effects of morphine glucuronides. Tohoku J Exp Med 105:45–52CrossRefGoogle Scholar
  18. 18.
    Osborne RJ, Joel SP, Slevin ML (1986) Morphine intoxication in renal failure: the role of morphine-6-glucuronide. Br Med J 292:1548–1549CrossRefGoogle Scholar
  19. 19.
    Shelly MP, Quinn K, Park GR (1989) Pharmacokinetics of morphine in patients following liver transplantation. Br J Anaesth 63:375–379PubMedCrossRefGoogle Scholar
  20. 20.
    Szeto HH, Inturrisi CE, Houde R, Saal S, Cheigh J, Reidenberg MM (1977) Accumulation of normeperidine, an active metabolite of meperidine, in patients with renal failure or cancer. Ann Intern Med 86:738–741PubMedGoogle Scholar
  21. 21.
    Alazia M, Levron JC, Quidon C, Francois G (1987) Pharmacokinetics of fentanyl during continuous infusion in critically ill patients. Anesthesiology 67:A665CrossRefGoogle Scholar
  22. 22.
    Stanski DR, Hug CC (1982) Alfentanil—a kinetically predictable narcotic analgesic. Anesthesiology 57:435–438PubMedCrossRefGoogle Scholar
  23. 23.
    Bodenham A, Park GR (1990) Plasma concentrations of bupivacaine after intercostal nerve block in patients after orthotopic liver transplantation. Br J Anaesth 64:436–440PubMedCrossRefGoogle Scholar
  24. 24.
    Hunter JM (1987) Infusions of atracurium and vecuronium in patients with multisystem organ failure in the intensive therapy unit. Insights into Anaesthesiology 1:23–26Google Scholar
  25. 25.
    Parker CJR, Jones JE, Hunter JM (1988) Disposition of infusions of atracurium and its metabolite, laudanosine, in patients in renal and respiratory failure in an ITU. Br J Anaesth 61:531–540PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1992

Authors and Affiliations

  • M. P. Shelly

There are no affiliations available

Personalised recommendations